Potassium iodide Renewal pills 100 mcg, 112 pcs.

Composition

Active ingredient: potassium iodide 131 mcg (corresponds to 100 mcg of iodine). Auxiliary substances:magnesium hydroxycarbonate (basic magnesium carbonate) – 0.0175 glactose monohydrate (milk sugar) – 0.059869 g microcrystalline cellulose-0.02 g magnesium stearate-0.001 g silicon dioxide colloidal (aerosil) – 0.0005 g croscarmellose sodium-0.001 g

Pharmacological action

Pharmacodynamicaiod refers to the vital trace elements necessary for the normal functioning of the thyroid gland. When iodides enter the cells of the epithelium of the thyroid follicle, iodine ions are oxidized under the influence of the enzyme iodide peroxidase to form elementary iodine, which is included in the tyrosine molecule. In this case, one part of the tyrosine radicals in thyroglobulin is iodized, resulting in the formation of tyronines, the main of which are thyroxine (T4) and triiodothyronine (T3). Thironins form a complex with the protein thyroglobulin, which is deposited in the colloid of the thyroid follicle. Iodine, which enters the body in physiological quantities, prevents the development of endemic goiter (associated with a lack of iodine in food); normalizes the size of the thyroid gland in newborns, children and adolescents; and also affects the T3/T4 ratio, the concentration of thyroid-stimulating hormone. Pharmacokinetics When taken orally, it is rapidly and completely absorbed in the small intestine and distributed in the intracellular space within 2 hours. It accumulates mainly in the thyroid gland (the concentration of iodide is more than 0.5 mg/g of tissue), as well as in the salivary and mammary glands, the gastric mucosa. Penetrates well through the placenta. It is mainly excreted by the kidneys (trace amounts are detected in the urine 10 minutes after administration,80% of the dose is excreted within 48 hours, the rest-within 10-20 days), partially – with secretions of salivary, bronchial, sweat and other glands.

Indications

• Prevention of iodine-deficient diseases, including endemic goiter (especially in pregnant and lactating women);
• prevention of recurrent goiter after its surgical removal or after the completion of goiter treatment with thyroid hormone preparations;
• treatment of diffuse euthyroid goiter in newborns, children, adolescents and young adult patients.

Use during pregnancy and lactation

During pregnancy and lactation, the need for iodine increases. Potassium iodide is prescribed according to indications in cases where the intake of iodine with food is less than 150-300 mcg/day. The drug penetrates well through the placenta and can cause the development of hypothyroidism and goiter in the fetus. Iodine is also excreted in breast milk. Therefore, during pregnancy and lactation, the drug should be used only in the recommended doses.

Contraindications

– Hypersensitivity to iodine;

severe thyrotoxicosis;

– hidden thyrotoxicosis (at doses above 150 mg/day);

– dermatitis herpetiformis;

toxic adenoma, nodular goiter when used in doses over 300 mg/day (with the exception of preoperative therapy the purpose of the blockade of the thyroid gland);

– hereditary diseases associated with intolerance to galactose, lactase deficiency or glucose-galactose malabsorption.

Potassium iodide should not be used for hypothyroidism, except in cases where the development of the latter is caused by a pronounced iodine deficiency. The use of the drug should be avoided during therapy with radioactive iodine, the presence or suspicion of thyroid cancer.

With caution

In patients with impaired renal function.

Side effects

When using the drug according to the indications in the recommended doses, the occurrence of side effects is unlikely. Allergic reactions may occur: rarely-skin rash, angioedema.

Interaction

Simultaneous administration of antithyroid drugs weakens the effect of potassium iodide (mutually). Potassium perchlorate and thiocyanate inhibit the absorption of iodine by the thyroid gland. Thyroid-stimulating hormone improves the absorption of iodine by the thyroid gland and stimulates the production of its hormones. Concomitant use of angiotensin-converting enzyme inhibitors (including captopril, enalapril, lisinopril) increases the risk of hyperkalemia. High doses of iodine combined with potassium-sparing diuretics can lead to hyperkalemia. Simultaneous therapy with high-dose iodine and lithium preparations contributes to the development of goiter and hypothyroidism. Potassium iodide reduces thyroid uptake of 131I and 123I.

How to take, course of administration and dosage

When determining the required dose of the drug, regional and individual characteristics of iodine intake with food should be taken into account. This is especially important when prescribing the drug to newborns and children under 4 years of age. Prevention of iodine deficiency diseases:

• Newborns and children: 50-100 mcg of iodine per day (½- 1 tablet of Potassium iodide 100 mcg);
• Adolescents and adults: 100-200 mcg of iodine per day (1 tablet of Potassium iodide 100 mcg or 1 tablet of Potassium iodide 200 mcg);
• During pregnancy and lactation: 100-200 mcg of iodine per day (1 tablet of Potassium iodide 100 mcg or 1 tablet of Potassium iodide 200 mcg).

Overdose

When the drug is administered at a dose of more than 150 mcg per day to patients with foci with functional autonomy in the thyroid gland, iodine-induced hyperthyroidism may develop. When treated with high doses of iodine (more than 1,000 micrograms per day), in some cases, iodine-induced goiter and hypothyroidism may develop. Chronic overdose can lead to the phenomenon of “iodism”: a metallic taste in the mouth, swelling and inflammation of the mucous membranes (rhinitis, conjunctivitis, gastroenteritis, bronchitis), acne, dermatitis, swelling of the salivary glands, fever, irritability.

Special instructions

Before starting treatment, it is necessary to exclude a malignant lesion of the thyroid gland, hyperthyroidism or nodular toxic goiter.

Against the background of therapy with the drug in patients with impaired renal function, hyperkalemia may develop (periodic monitoring of the concentration of potassium in the blood is necessary).

Due to the presence of lactose monohydrate in the drug, patients with rare hereditary diseases associated with galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take the drug.

Influence on the ability to drive vehicles and mechanisms

The drug does not affect the ability to drive vehicles and engage in other potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Storage conditions

In a dark place at a temperature not exceeding 25 °C. Keep out of reach of children.

Shelf

life is 3 years.

Active ingredient

Potassium iodide

Dosage form

Tablets

Weight

Weight: 32 gr.